Oeceafcer 1-2, 1994, Data Management Report -- Page 10 
Attadmant 
IV - Rage 10 
c. 
Protocol 
Statue 
Open 
Pending j 
FDA 
Approval 
7 1 
III 
Pending 
FDA 
Approval 
Pending 
NIH 
approval 
Pending 
FDA 
approval 
(* chang- 
ing vector 
supplier) 
Teopora- 
rlly | 
closed by 
FDA 
f Deaths 
< 
z 
< 
z 
< 
Z 
VN 
VN 
< 
Z 
O 
Adverse 
i Effects 
< 
z 
< 
z 
VN 
VN 
< 
z 
< 
z 
Yes 
transient 
eimingeel 
inf lemmatory 
response to 
VPC 
Problems 
Associated 
With Gene 
Transfer 
< 
z 
< 
z 
< 
z 
VN 
VN 
< 
z 
No 
Evidence Of 
Biological 
Activity 
< 
z 
< 
z 
VN 
VN 
< 
z 
< 
z 
0 
z 
In Vivo Evidence Of 
Gene Transfer And 
Expression In 
Target Cells 
NA 
< 
z 
VN 
VN 
VN 
VN 
No 
Patients 
Entered On 
Study 
o 
© 
o 
o 
O 
o 
l. 
0 
ilL 
m 
zv* 
III 
ill 
IM Z 
00 £ 
6 
<M/F> 
r-j x 
o 5 
O X 
PO W 
V. 
0 X 
eg w 
si 
n 
] 
X 
GTI 
GTI 
U. 1L 
3 
0 
Vector Construct 
Packaging Cell Line 
(Delivery Vehicle) 
oj ~ < 
si 1 
8 8 I 
it i 
x a. — 
&S t 
G1MD 
PA317 
(Retrovirus) 
GITkSvNa 
PA317 
(Retrovirus) 
rg 
i » i 
8 | 1 
i El t 
— ♦ 4i 
1 S 5 
pMJT 
PA317 
(Retrovirus) 
V 
i 
^ ^ ' 
GITkSvNa 
PA317 
(Retrovirus) 
Dates of 
Treatment: 
(1) first Patient 
(2) Host Recent 
Patient 
< 
z 
< 
z 
< 
Z 
< 
Z 
VN 
< 
z 
* 
CO 
< 
CO z 
•- eg 
Category 
T/V/C 
SCIC 
T/C 
(Breast) 
T/C 
(Brain) 
T/V/C 
(Melanoma) 
AIH /1 
T/V/C 
(Melanoma) 
T/C 
(1C) 
2 
« 
o 
L i i 
5 a s e 
PO 
Os m 
o* a 
rg « 
f a " 
2: c 5 
a = 2 
ec z u. 
RAC/9-9-93 
NIH/10-7-93 
FDA/Pendlrvg 
RAC/9-9-93 
NIH/10-7-93 
F0A/5- 18-94 
RAC/9-10-93 
NIH/4-19-94 
FOA/Pendlng 
RAC/9-10-93 
NIH/Pending 
FDA/ 
RAC/9-10-93 
M 1 M/12-2-93 
FDA/Pending 
RAC/12-2-93 
NIH/1-20-94 
FDA/ 
pi/ 
Institution 
X 
Ij J 
*0 0 X 
• • 
0 w 
U « 3 
>* 
0 
0 
S 
? 
X 
V) z 
o z 
Km, et.al./ 
St. Jude 
0 
9 -^ 
O — -J 
0 — 
0 a 
0 
o i» 3 
Uong-Staal, 
et. al./ 
USD 
"0 
0 
c < 
0 — 1 
u 0 
UJ 3 
HIN 
/•l«’)»'P)»t|P 10 
m m 
i 8 
! 2 
w 
jS) 
1 i 
8 i 
9309-054 
(Pending) 
9309-055 
(5512) 
9309-056 
(Pending) 
9309-057 
9309-058 
(Pending) 
9312-059* 
(5448) 
